Wallace Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Wallace Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,175	Closed	-$2.26M	–	84
2023 Q2	$2.26M	Buy	+22,175	New	+$2.1M	0.35%	36
2019 Q3	–	Sell	-7,255	Closed	-$685K	–	70
2019 Q2	$685K	Sell	7,255 -500	-6%	-$43.2K	0.09%	44
2019 Q1	$663K	Hold	7,755	–	–	0.09%	43
2018 Q4	$435K	Hold	7,755	–	–	0.06%	48
2018 Q3	$634K	Buy	7,755 +5	+0.1%	+$352	0.08%	47
2018 Q2	$271K	Buy	+7,750	New	+$236K	0.04%	63

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wallace Capital Management's RETA Position: Q3 2023 in Review

Wallace Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 22,175 shares — an estimated $2.26M sold.

Wallace Capital Management first reported a position in RETA in Q2 2018 and held it in 6 quarters. The position peaked at $2.26M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Wallace Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Wallace Capital Management sold 22,175 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.26M.
Wallace Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 6 quarters.
Wallace Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.26M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Wallace Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.